Here, we developed a trispecific antibody that interacts with CD38, CD3 and CD28 to enhance both T cell activation and tumor targeting. The engagement of both CD3 and CD28 affords efficient T cell stimulation, whereas the anti-CD38 domain directs T cells to myeloma cells, as well as to ...
We then conducted antibody-dependent cell cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP) assays and found that the trispecific bNAb had comparable or better activity compared to its parental bNAbs alone. Similarly, when we measured direct virolysis of HIV-1 virus using an ...
“We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma” “SIM0500 is developed via Simcere Zaiming’s...
SHANGHAIandNORTH CHICAGO, Ill.,Jan. 13, 2025/PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE:ABBVChinaand the U.S. SIM0500 is a humanized trispecific antibody that t...
Here we demonstrate that a trispecific antibody to HER2, CD3 and CD28 stimulates regression of breast cancers in a humanized mouse model through a mechanism involving CD4-dependent inhibition of tumour cell cycle progression. Although CD8 T cells directly mediated tumour lysis in vitro, CD4 T cells...
" saidMariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology,AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with...
" saidMariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help addre...
On March 31, 2024, pre-clinical research results of the tri-specific antibody DR30318 independently developed by Zhejiang Doer Biologics Co., Ltd. (Doer Bio), were published in Cancer Immunology,Immunotherapy, an high-impact journal in the field of tumor immunotherapy (2022 JCR lmpact Factor ...
On March 31, 2024, pre-clinical research results of the tri-specific antibody DR30318 independently developed by Zhejiang Doer Biologics Co., Ltd. (Doer Bio), were published in Cancer Immunology,Immunotherapy, an high-impact journal in the field of tumor immunotherapy (2022 JCR lmpact Factor ...
On March 31, 2024, pre-clinical research results of the tri-specific antibody DR30318 independently developed by Zhejiang Doer Biologics Co., Ltd. (Doer Bio), were published in Cancer Immunology,Immunotherapy, an high-impact journal in the field of tumor immunotherapy (2022 JCR lmpact Factor ...